Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Emergence of PALB2 Reversion Mutations as a Mechanism of Resistance to Niraparib in Breast Cancer: A Case Report

Cancer Science(2025)10.1111/cas.70210Source: DataRank Database

Emergence of PALB2 Reversion Mutations as a Mechanism of Resistance to Niraparib in Breast Cancer: A Case Report is a research paper published in Cancer Science (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

0 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:OA: goldTopics (1)IDs (PubMed)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Hiroshi Tada,Hidekazu Shirota ORCID,Miki Dobashi,Noriko Takenaga,Hiroyuki Yasojima

Live enrichment

PubMed:41048130

goldLicense: cc-by-nc

GOLDhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cas.70210

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cas.70210

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.70210

Fields of Study

Medicine

Emergence of PALB2 Reversion Mutations as a Mechanism of Resistance to Niraparib in Breast Cancer: A Case Report

FAIR Checklist

Authors (11)

Open Access

Topics